Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis
GUS-mediated improvements in anxiety, depression, and overall HRQoL are not solely mediated by resolution of PsO signs, suggesting GUS use has a potential direct effect on anxiety and depression.
Authors
- Chenglong Han (ORCID: https://orcid.org/0000-0001-7175-7834)
- Kim Papp (ORCID: https://orcid.org/0000-0001-9557-3642)
- Mitchell D. Miller (ORCID: https://orcid.org/0000-0003-1626-4943)
- Kenneth B. Gordon (ORCID: https://orcid.org/0000-0002-9347-0292)
- Rachel E. Teneralli (ORCID: https://orcid.org/0000-0003-4340-9001)
- April Wang Armstrong (ORCID: https://orcid.org/0000-0003-0064-8707)
- Anthony Bewley (ORCID: https://orcid.org/0000-0003-1195-0290)
- Yan Liu (ORCID: https://orcid.org/0009-0000-5377-864X)
- Peter Foley
Institutions
- University of California, Los Angeles (US)
- The University of Melbourne (AU)
- Medical College of Wisconsin (US)
- Barts Health NHS Trust (GB)
- St Vincent's Hospital Melbourne (AU)
- Probity Medical Research (CA)
- LifeSensors (United States) (US)
- Janssen (United States) (US)
- Skin Health Institute (AU)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1007/s13555-024-01250-9
- Citations
- 6
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 1.44
Funders
- Janssen Scientific Affairs
- Janssen Pharmaceuticals